|
WO2008066704A2
|
|
Method of improving bioavailability for non-sedating barbiturates
|
|
WO2007136824A1
|
|
High-yield bacitracin-producing microorganism
|
|
WO2007127293A2
|
|
Novel streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria
|
|
WO2007092318A2
|
|
Spill resistant antibiotic formulations
|
|
WO2007008576A2
|
|
Oxcarbazepine formulation
|
|
WO2006110534A2
|
|
A process for preparing a crystalline form of halobetasol propionate
|
|
EP1863434A2
|
|
A stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
|
|
WO2007000662A2
|
|
Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
|
|
US7758877B2
|
|
Stable loratadine spill resistant formulation
|
|
CA2791779A1
|
|
Spill resistant formulations containing clays
|
|
US7687628B2
|
|
Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof
|
|
WO2005019089A2
|
|
Tip applicator with a venturi structure
|
|
CA2519712A1
|
|
Process to prepare a skin softening composition
|
|
US2004186120A1
|
|
Method of treating movement disorders using barbituric acid derivatives
|
|
CN101862292A
|
|
Ibuprofen suspension
|
|
AU2003240009A1
|
|
Method of preparing a 5h-dibenz(b,f)azepine-5-carboxamide
|
|
EP1465855A2
|
|
Method for the production of 6-alpha-fluoro corticosteroids
|
|
IL157555D0
|
|
Process for purification of warfarin acid, warfarin alkali metal salts and corresponding clathrates
|
|
AU1831299A
|
|
Topical carbamazepine formulations and methods of use
|
